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Primary hyperparathyroidism (PHPT) is a frequent endocrine disorder characterized by an excessive autonomous production and
release of parathyroid hormone (PTH) by the parathyroid glands. This endocrinopathy may result from the development of a
benign lesion (adenoma or hyperplasia) or from a carcinoma. Most of the PHPT cases occur sporadically; however, approximately
10% of the patients present a familial form of the disease. The molecular mechanisms underlying the pathogenesis of sporadic
PHPT are incompletely understood, even though somatic alterations in MEN1 gene and CCND1 protein overexpression are
frequently observed. The MEN1 gene is mutated in about 30% of the parathyroid tumours and the protooncogene CCND1 is
implicated in parathyroid neoplasia by rearrangements, leading to an overexpression of CCND1 protein in parathyroid cells. The
aim of this work is to brieﬂy update the molecular alterations underlying sporadic primary hyperparathyroidism.
1.Introduction
One of the multiple implications of multicellularity is that
all parts of a body must be able to communicate with each
other,inordertomaintainhomeostasis.Thecommunication
between diﬀerent parts of an organism is essential for an
appropriate response to internal and external environmental
stimuli. The endocrine system, through the production, and
release of hormones, is a key element for the establishment
and maintenance of such regulation [1].
The parathyroid glands are the endocrine organs respon-
sible for regulating calcium levels by producing a hormone,
the parathyroid hormone (PTH), released directly into the
blood [2] that regulates calcium levels acting at various
organs.
Calcium plays a fundamental role in controlling the
neuromuscular activity, the blood clotting process, bone
structure, and integrity of cell signaling. The levels of
ionized calcium in bloodstream are maintained by a com-
plex hormonal mechanism, involving three main systems:
gastrointestinal system, bone, and kidney [3, 4].
Primary hyperparathyroidism is a common endocrin-
opathy characterized by an inappropriate oversecretion of
PTH. High PTH levels lead to a hypercalcemic state aﬀecting
diﬀerent organs and systems such as bones and kidneys and
cardiovascular, gastrointestinal, and nervous systems [5, 6].
The incidence of PHPT is estimated as 25 cases per
100000 individuals, and the main risk factors are older age,
female gender, and exposure to cervical irradiation [7, 8].
This pathological condition, in 80 to 85% of the cases,
is due to a parathyroid adenoma (uniglandular disease),
followed by 15 to 20% of cases arising due to hyperplasia
(multiglandular disease) and rarely, in 2 to 5% of cases, can
be caused by a carcinoma [4].
Most of the PHPT cases belong to sporadic forms of the
pathology, but about 10% of the cases are familial forms [7].
Germline genetic alterations in MEN1 (multiple endo-
crine neoplasia type 1) gene are associated with PHPT in
the context of MEN1 syndrome, and mutations in HRPT2
(hyperparathyroidism 2) gene are associated with HPT-JT
(Hyperparathyroidism-Jaw tumor) familial syndrome. The
development of PHPT in the context of MEN2 (multiple2 Genetics Research International
Table 1: Summary of the molecular alterations associated with familial and sporadic parathyroid tumors.
MEN1 [20, 50–52] CCND1
[31, 53–55] HRPT2 [13, 56–58] RET [48] CaSR [49, 59–61]
Germline mutations Inactivating
mutations, LOH — Inactivating
mutations, LOH
Activating
mutations
Inactivating
mutations
(Familial syndrome) (MEN1) (HPT-JT) (MEN2A) (NSHPT/FHH)
Benign
Somatic mutations Inactivating
mutations, LOH
Activating Inv (11)
(p15; q13)
Inactivating
mutations NN
Prevalence of somatic
alteration 20 to 30% ∼5% 2 to 4% — —
Protein expression
(%)
Downregulation
(20 to 40%)
Overexpression (30
to 40%)
Downregulation
(ND) ND Downregulation
(Up to 90%)
Malignant
Somatic mutations Inactivating ND Inactivating
mutations, LOH NN D
Prevalence of somatic
alteration
∼13% ND 70 to 100% — —
Protein expression
(%) ND Overexpression
(∼90%)
Downregulation/loss
of expression
(70 to 100%)
ND Downregulation
(∼30%)
N: negative; ND: not determined.
endocrine neoplasia type 2) syndrome, speciﬁcally in the
variant MEN2A, is associated with genetic alterations in
the RET (rearranged during transfection) gene. Homozy-
gous or heterozygous mutations in CaSR (Calcium Sensing
Receptor) gene are the source of NSHPT (neonatal severe
hyperparathyroidism) and FHH (familial hypercalcemic
hypercalciuric), respectively [9, 10].
Although, the genetic alterations associated with familial
forms are well known, the genetic alterations underlying
sporadic forms are far from being understood. The molec-
ular alterations that are established as being characteristic of
sporadic benign parathyroid tumor are genetic alterations in
the MEN1 gene (20 to 30% cases) and Cyclin D1 protein
overexpression (30 to 40% of cases) [11, 12]. Parathyroid
carcinomas are strongly associated with somatic HRPT2
mutations [13].
1.1.TheRoleofMEN1GeneinPHPT. TheMEN1tumorsup-
pressorgenewasidentiﬁedin1997asthegeneresponsiblefor
the autosomal dominant syndrome characterized by tumors
ofendocrinepancreas,theanteriorpituitaryandparathyroid
glands,theMEN1syndrome[14].Apartfrombeinginvolved
in the mentioned familial syndrome, somatic mutations
of MEN1 gene are also implicated in the development of
sporadic parathyroid tumors [15].
The MEN1 gene is located on chromosome 11 (band
11q13), consists of 10 exons (with 9 coding exons), and
encodes a protein of 610 amino acids called menin that is
ubiquitouslyexpressed,atallstagesofdevelopment[16].The
transcript of MEN1 gene is a 2.8Kb mRNA but six more
alternative transcripts have been reported, although none of
theminterfereswiththecodingregionrevealingvariationsof
the 5  translated region only [17]. Despite the high degree of
conservationamongmetazoan,menindoesnotrevealmotifs
of known function and has no similarity with any other
known protein [18].
Tumors of MEN1 patients usually reveal the presence of
a germline mutation followed by a somatic alteration such
as loss of heterozygosity (LOH) or inactivating mutation, as
predicted by the model of Knudson, pointing to MEN1 gene
as a very good example of a classical tumor suppressor gene
[19].
About 30% of sporadic parathyroid tumors show MEN1
gene mutations (see Table 1). These somatic mutations,
similarly to what happen with the germline mutations, are
spread throughout the coding region. About 40% of these
mutations are frameshift, 29% are missense mutations, 18%
are nonsense, 7% occur in splice sites, and 6% are deletions
or insertions in-frame. Sporadic parathyroid tumors harbor-
ing MEN1 gene somatic mutations frequently evidence LOH
on chromosome region 11q13 [20]. Somatic inactivating
mutations in this gene have also been identiﬁed in other
types of tumors, namely, in neuroendocrine tumours such
as gastrinomas, insulinomas, lung carcinoids, and pituitary
tumors showing a similar loss of function mechanism
promoting tumorigenesis [21–23].
From Drosophila to humans, menin is conserved but is
absent in C.elegans and yeast [24]. Subcellular localization
studies evidence that the protein has predominantly a
nuclear localization and possesses two nuclear localization
signals (NLSs) that should be essential for its role in regu-
lation of gene transcription [25]. Menin has been reported
to interact with a broad spectrum of proteins involved
in regulation of transcription by coordinating chromatin
remodeling, genome stability, cell division, and proliferation
[26, 27].Genetics Research International 3
Recently, it was demonstrated in vitro that menin acts as
as c a ﬀold and inhibits AKT/PKB activation by regulating its
cellular localization, since it hampers the transition from the
cytoplasm to the membrane, required to its activation [28].
The clinical relevance of pathways and molecular mech-
anisms in which menin is involved remain to be clariﬁed.
Most of the MEN1 gene mutations will lead to a
premature stop codon, giving rise to a truncated protein.
Frequently this truncated menin may have lost, at least one
of its NLS, compromising the protein function, regarding
their role of driving the protein to the nucleus, but also by
coordinating the regulation of expression of menin target
genes [25].
Menin protein can function as suppressor of transcrip-
tion, because this protein is able to bind a family of tran-
scription factors such as AP-1/Jun-Fos family, and it is also
associated with a histone methyltransferase (HMT) complex
leading to an increased expression of cyclin-dependent
kinase inhibitors (CDKIs) and consequently suppressing cell
growth [29, 30].
1.2. The Role of Cyclin D1 Protein in PHPT. The gene
encoding cyclin D1, CCND1, located in chromosome 11q13,
was initially designated PRAD1 (parathyroid adenomatosis 1)
since it was cloned from DNA from a parathyroid adenoma.
In 1989, Arnold and colleagues found a genetic rearrange-
ment in a parathyroid adenoma, this rearrangement, inv
(11) (p15; q13), positions the 5  PTH gene regulatory region
(located in 11p15) adjacent to the CCDN1 gene leading to
the overexpression of cyclin D1 protein [31]. The increased
expression of cyclin D1 promotes the transcription of genes
required for DNA synthesis and cell cycle progression.
Several studies show the overexpression of cyclin D1 in
20–40% of parathyroid tumors (see Table 1), even though
they do not demonstrate the presence of the rearrangement,
pointing to the presence of other molecular abnormalities
leading to an overexpression of this cell cycle regulator [32].
The pathogenic role of this protein was assessed through
studies in transgenic mice overexpressing cyclin D1 in
parathyroid. These mice were created to model the genetic
rearrangement found in human parathyroid tumors [33].
In this model, the overexpression of this cell cycle regulator
leads to hyperplasic parathyroid glands, with increased cell
proliferation, retaining their capacity of hormone produc-
tion [34].
1.3. Parathyroid Carcinoma and CDC73/HRPT2. In 2002,
germline mutations in the tumor suppressor gene hyper-
parathyroidism 2 (HRPT2)w e r ed e s c r i b e db yC a r p t e ne ta l .
as being responsible for the HPT-JT familial syndrome [13].
HRPT2 gene is located at 1q25-q31 and encodes a 60kDa
nuclear protein named paraﬁbromin that has been shown
to be a member of the polymerase-associated factor (PAF1)
complex involved in gene transcription regulation by histone
ubiquitination and methylation [35, 36].
Additionally, paraﬁbromin suppresses tumor growth by
inducing apoptosis, inhibiting G1 to S phase transition,
regulating Wnt canonical pathway, and also regulating gene
expression by direct binding of promoter regions, being
therefore expected that loss of paraﬁbromin will lead to
enhanced cellular proliferation [37–40].
The loss of paraﬁbromin as a molecular marker of
parathyroid carcinoma was ﬁrst reported by Tan and col-
leagues in 2004. These authors noted that loss of paraﬁ-
bromin nuclear staining had a high sensitivity and speciﬁcity
for the deﬁnitive diagnosis of parathyroid carcinoma and
their results were conﬁrmed by other groups [41, 42].
Despite its speciﬁcity, other studies indicated that,
although occurring more frequently in parathyroid carcino-
mas, loss of paraﬁbromin nuclear staining can also occur in a
smallproportionofsporadicbenignadenomasandtherefore
cannot be considered exclusive of malignancy. Curiously,
these adenomas exhibit cystic features which are commonly
observed in the HPT-JT syndrome [43]. Another important
aspect is the fact that nuclear positivity cannot exclude the
presence of HRPT2 mutation, once some tumors harboring
missense mutations revealed weak nuclear positivity [44].
Given the low frequency of parathyroid carcinomas,
these are commonly misdiagnosed in the clinical setting
and the need of speciﬁc markers for this disease is funda-
mental to reduce potential false-negative cases [45]. Some
studies assessed the role of additional molecular marker to
complement paraﬁbromin staining in the screening process,
emerging the protein 9.5 (PGP9.5) encoded by the ubiquitin
carboxyl-terminal esterase L1 (UCHL1), that was found to be
upregulated in the majority of parathyroid carcinomas [46].
In contrast, the tumor suppressor adenomatous polyposis coli
(APC)wasfounddownregulatedincarcinomaswhilebenign
lesions retain the expression [47].
In spite of these ﬁndings, the unequivocal diagnosis
remains a challenge, and additional markers are likely to
increase the knowledge and proper recognition of parathy-
roid carcinomas.
2. The Role of Other Genes in PHPT
The knowledge on the molecular bases of parathyroid
tumorigenesis, particularly the sporadic variant, remains
largely unknown. Some candidate genes have been studied
because of their possible role in sporadic primary hyper-
parathyroidism development (see Table 1). Despite their
involvement in familial forms, no somatic mutations have
been found in RET and CaSR genes [48, 49].
Vitamin D receptor (VDR) has an important role in
negatively controlling PTH secretion and parathyroid prolif-
eration, thus representing a good target for this parathyroid
pathological condition, but no mutations in either VDR
geneorvitamin-D-activatingenzymewerefoundinsporadic
parathyroid tumors despite the evidence of the reduced
expression in some series [62–65].
Abnormal Wnt signaling has been associated with many
types of tumors, and deregulation of CTNNB1 as well as
mutations of LRP5 coreceptor has been found in some series
ofparathyroidtumors.Atvariance,otherstudiespointedout
that Wnt/beta-catenin signaling does not seem to contribute
to the development of parathyroid tumors [66–68].
The existence of common molecular alterations among
endocrine tumors and its proximity with MEN1 gene4 Genetics Research International
raised the hypothesis that SDH5 gene could be involved in
parathyroid tumorigenesis, but no genetic alterations were
found in this pathology [69].
Using techniques such as comparative genomic hybrid-
ization(CGH),variousauthorsveriﬁedthepresenceofchro-
mosome gains and losses in speciﬁc regions, suggesting the
presence of unidentiﬁed oncogenes and tumor suppressor
genes, which may have a role in parathyroid tumorigenesis.
Chromosomal regions in 1p, 6q, 9p, and 13q were found
to be lost in benign and malignant parathyroid lesions,
indicating these chromosomal regions as eventual carriers
of novel tumor suppressor genes. Unknown oncogenes may
be present in chromosomal regions of 9q, 16p, and 19p,
because several authors demonstrated gain in these loci, in
parathyroid tumors [70–72].
Chromosomal imbalances have been recognized as a
mechanism able to alter the expression of miRNAs. Corbetta
and collaborators explored the miR expression proﬁle in
parathyroid carcinomas, since the expression of these small
noncoding RNAs varies between cancer and normal cells.
These authors went to verify diﬀerential expression among
parathyroid carcinoma and normal tissue. By real-time PCR,
it was observed that the overall miRNA expression could
separate normal versus cancer tissue and four miRs (miR-
296, miR-139, miR-222, and miR-503) revealed diﬀerences
between tumoural and normal parathyroid tissues [73].
S o m eg e n e ss u c ha shuman growth factor-regulated tyrosine
kinase substrate (HGS)a n dp27/Kip1 are described as poten-
tial targets of these miRNAs but further information about
thebiologicalrelevanceoftheseﬁndingsisneededandmight
provide tools for identifying new diagnostic and therapeutic
strategies [74, 75].
Most of the studies in parathyroid tumorigenesis ﬁeld
have been performed using genomics and immunohis-
tochemical approaches [53, 76]. Giusti and collaborators
carried out comparative analysis to examine the changes in
protein proﬁle between adenomas and normal parathyroid
tissue [77]. These authors veriﬁed the presence of 30
deregulated proteins in parathyroid adenomas, 22 of them
being overexpressed when compared to normal parathyroid
tissue [77]. Some of the identiﬁed proteins belong to the
same functional class of the ones identiﬁed by Haven and co-
workers when they preformed tissue microarrays for benign
and malignant tumors [78]. Overall, these ﬁndings represent
promisingstepsfortheimprovementoftheknowledgeabout
this pathology.
3. Concluding Remarks
Presently, alterations in MEN1 and CCND1 are still the
main genetic alterations associated with the development of
sporadic benign tumors (accounting for approximately 30%
of the cases). The HRPT2 gene is not only responsible for
the HPT-JT syndrome but also mutated in the majority of
parathyroid carcinomas.
Anumberofothercandidategenes(duetotheirgenomic
localization, role in familial syndromes, and/or biological
function) have been studied in parathyroid tumors, but
without promising results.
Future goals include the identiﬁcation of additional
oncogenes and/or tumor suppressor genes in parathyroid
lesions and understanding the molecular insights in the
relationship between parathyroidproliferation andhormone
regulation.
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